This technology features a composition for alleviating and preventing acne that uses phenylacetaldehyde or its salts as an active ingredient to inhibit skin inflammation caused by the acne-causing bacterium Cutibacterium acnes. It encompasses cosmetic, pharmaceutical, and quasi-drug compositions, as well as methods for treating acne by applying the substance to the skin in forms such as patches or creams.
Acne worsens through a chain reaction of excess sebum secretion, clogged hair follicles, bacterial proliferation, and inflammation, often leaving scars and hyperpigmentation if left untreated. While antibiotics like clindamycin and erythromycin, as well as benzoyl peroxide and azelaic acid, have been used, they are often associated with significant skin irritation.
This technology is based on the discovery that phenylacetaldehyde inhibits the expression of NF-κB and inflammatory cytokine genes such as IL-6, IL-1β, IL-8, and TNF-α, which are activated by acne bacteria. By suppressing inflammatory signals at the transcriptional level, it focuses on calming red inflammation before it develops into papules or pustules. It can be applied to spot patches, soothing toners, and acne-specific sheet masks, allowing for the development of daily trouble-care products that do not rely on harsh antibiotics.
N/A
